Tavros employs an integrated high-throughput functional genomics discovery platform to uncover unique weaknesses in cancer cells that are exposed by drug treatment. These context-specific vulnerabilities point us to a clear clinical path for novel drug development with the knowledge of predictive biomarkers and optimal drug combinations that improve therapeutic response. We use this dynamic discovery engine to identify first-in-class drug targets with a clear path forward to the clinic to get the right drugs to the right patients, faster.
Starting with vetted, druggable targets dramatically reduces time to IND
Tavros’ drug discovery programs are focused on using our drug-first functional genomics screening approach to discover novel drug targets in strategic, underserved areas in cancer biology.